Amylin Pharmaceuticals, Eli Lilly and Alkermes announced new analyses from the DURATION-3 and DURATION-4 trials demonstrating patients treated with the investigational medication Bydureon (exenatide extended-release for injectable suspension) experienced significant improvements in select cardiovascular risk factors, in comparison to patients who received commonly prescribed diabetes treatments...
Category: Insulin
The Juvenile Diabetes Research Foundation (JDRF) and InnoCentive, Inc., the pioneer in open innovation and crowdsourcing, announced a $100,000 Challenge calling for innovative ways to approach the discovery and development of a glucose-responsive insulin drug as a means to treat insulin-dependent diabetes. The Challenge is open to the public and can be found on the InnoCentive website...
MannKind Corporation announced that it has confirmed with the U.S. Food and Drug Administration the design of two clinical studies that evaluate the efficacy and safety of AFREZZA (insulin human [rDNA origin]), an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind's next-generation inhaler...
The European Commission has approved Novo Nordisk's new prefilled insulin pen – FlexTouch for use in the EU. The approval is for NovoRapid® (insulin aspart) and Levemir® (insulin detemir) - both modern insulins currently delivered in FlexPen.
FlexTouch, the latest prefilled delivery system from Novo Nordisk, offers a new insulin injection experience for users...
InsuLine Medical, an Israeli based company whose mission is to develop and market technologies for type 1 and type 2 diabetes, announced that it has completed a first stage clinical trial to examine the effectiveness of its InsuPatch for adults with type 1 diabetes...
Treating type 1 and type 2 diabetes with investigational ultra rapid acting mealtime insulin Afrezza (insulin human [rDNA origin]) Inhalation Powder does not result in excess cardiovascular events according to two new studies being presented at the American Diabetes Association's...
The U.S. Food and Drug Administration (FDA) approved Eli Lilly's supplemental new drug application (sNDA) for Humalog(R) (insulin lispro injection [rDNA origin]).
Based on the updated label, people with type 1 diabetes using Humalog for pump therapy can use the insulin in the pump reservoir for up to seven days...
Biodel announced that an independent investigator initiated a pump trial of Biodel's two ultra-rapid-acting formulations of recombinant human insulin. Biodel's formulations, BIOD-105 and BIOD-107, are designed to result in more rapid insulin action compared to currently marketed mealtime insulin analogs...
New clinical trial data just published in Pediatric Diabetes shows that Levemir (insulin detemir), Novo Nordisk’s basal insulin analogue, is an equally efficacious treatment option for two to five year-old children with type 1 diabetes, compared with human basal insulin, but is associated with lower hypoglycemic risk. Children with type 1 diabetes who are aged under six years...
Biodel Inc. has selected two new formulations of recombinant human insulin for clinical testing and is accelerating clinical development plans of these mealtime insulin drug candidates.
The new formulations, BIOD-105 and BIOD-107, are designed to result in more rapid insulin action compared to currently marketed...